Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment

Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface, predominantly caused by prior asbestos exposure. There is a global epidemic of malignant pleural mesothelioma underway, and incidence rates are predicted to peak in the next few years. This article summarises the epidemiology and pathogenesis of malignant pleural mesothelioma, before describing some key factors in the patient experience and outlining common symptoms. Diagnostic approaches are reviewed, including imaging techniques and the role of various biomarkers. Treatment options are summarised, including the importance of palliative care and methods of controlling pleural effusions. The evidence for chemotherapy, radiotherapy and surgery is reviewed, both in the palliative setting and in the context of trimodality treatment. An algorithm for managing malignant pleural effusion in malignant pleural mesothelioma patients is presented. Finally new treatment developments and novel therapeutic approaches are summarised. This article on mesothelioma describes pathogenesis, symptoms, diagnostic approaches and treatment options http://ow.ly/cjkb305aQGz

[1]  E. Yorke,et al.  Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Maskell,et al.  What is the role of a specialist regional mesothelioma multidisciplinary team meeting? A service evaluation of one tertiary referral centre in the UK , 2016, BMJ Open.

[3]  N. Maskell,et al.  Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial , 2016, The Lancet. Oncology.

[4]  Nick A Maskell,et al.  Pleural biopsies in undiagnosed pleural effusions; Abrams vs image-guided vs thoracoscopic biopsies , 2016, Current opinion in pulmonary medicine.

[5]  H. Jones,et al.  Interventions for the management of malignant pleural effusions: a network meta-analysis. , 2016, The Cochrane database of systematic reviews.

[6]  M. Zauderer A new standard for malignant pleural mesothelioma , 2016, The Lancet.

[7]  B. Milleron,et al.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.

[8]  Sharyn I. Katz,et al.  Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy , 2016, Clinical Cancer Research.

[9]  R. Flores The mesothelioma surgery shift. , 2016, The Journal of thoracic and cardiovascular surgery.

[10]  R. Flores Pleurectomy decortication for mesothelioma: The procedure of choice when possible. , 2016, The Journal of thoracic and cardiovascular surgery.

[11]  M. Metintaş,et al.  Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy. , 2016, The Journal of thoracic and cardiovascular surgery.

[12]  A. Hope,et al.  Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. , 2016, The Journal of thoracic and cardiovascular surgery.

[13]  R. Hallifax,et al.  Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial. , 2015, JAMA.

[14]  K. Nackaerts,et al.  Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. , 2015, The Lancet. Oncology.

[15]  A. Clive,et al.  S19 Interventions for the management of malignant pleural effusions , 2015 .

[16]  M. Maio,et al.  16TiPA phase II study combining tremelimumab and durvalumab (MEDI4736) immunomodulating antibodies in mesothelioma patients: The NIBIT-MESO-1 study , 2015 .

[17]  M. Valsecchi Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[18]  J. Schellens,et al.  Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028 , 2015 .

[19]  J. Braybrooke,et al.  Medical and oncological management of malignant mesothelioma. , 2015, British journal of hospital medicine.

[20]  N. O'Rourke,et al.  Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  R. Hubbard,et al.  Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales. , 2015, Lung cancer.

[22]  K. McDougall,et al.  Mesothelin-targeted immunotherapy CRS-207 in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM). , 2015 .

[23]  L. Emens,et al.  The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies , 2015, Cancer Immunology Research.

[24]  M. Maio,et al.  Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. , 2015, The Lancet. Respiratory medicine.

[25]  W. Keeratichananont,et al.  Efficacy and safety profile of autologous blood versus tetracycline pleurodesis for malignant pleural effusion , 2015, Therapeutic advances in respiratory disease.

[26]  C. Dooms,et al.  Malignant pleural mesothelioma: visual assessment by using pleural pointillism at diffusion-weighted MR imaging. , 2015, Radiology.

[27]  J. M. Porcel,et al.  Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis. , 2015, Chest.

[28]  M. Meyerson,et al.  Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. , 2015, Cancer research.

[29]  S. Steinberg,et al.  Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125 , 2014, Cancer.

[30]  L. Sharples,et al.  Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial , 2014, The Lancet.

[31]  N. Maskell,et al.  A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial , 2014, Trials.

[32]  I. Pastan,et al.  Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma , 2014, Clinical Cancer Research.

[33]  K. Nackaerts,et al.  1074TiPRANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TREMELIMUMAB FOR SECOND-LINE AND THIRD-LINE TREATMENT OF UNRESECTABLE PLEURAL OR PERITONEAL MESOTHELIOMA. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  S. Skates,et al.  Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma , 2014, Thorax.

[35]  A. Tsao,et al.  Randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment of unresectable pleural or peritoneal mesothelioma. , 2014 .

[36]  M. Tsao,et al.  A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” Approach for Resectable Malignant Pleural Mesothelioma , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[37]  Kan Zhai,et al.  Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis , 2014, BMJ Open.

[38]  T. Yan,et al.  A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. , 2014, Lung cancer.

[39]  Victoria Keena,et al.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. , 2013, Journal of thoracic disease.

[40]  D. Torigian,et al.  Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.

[41]  M. Maio,et al.  Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. , 2013, The Lancet. Oncology.

[42]  A. Arber,et al.  ‘It's all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma , 2013, Psycho-oncology.

[43]  James Murray Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma , 2013, Thorax.

[44]  V. Rusch,et al.  Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[45]  Stephen A. Williams,et al.  Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool , 2012, PloS one.

[46]  T. Yan,et al.  Systematic review of trimodality therapy for patients with malignant pleural mesothelioma. , 2012, Annals of cardiothoracic surgery.

[47]  A. Musk,et al.  A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[48]  B. Kahan,et al.  Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. , 2012, JAMA.

[49]  N. Maskell Treatment options for malignant pleural effusions: patient preference does matter. , 2012, JAMA.

[50]  C. Dooms,et al.  Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging--initial experience. , 2012, Radiology.

[51]  K. Nackaerts,et al.  Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  P. Rascoe,et al.  Molecular pathogenesis of malignant mesothelioma , 2012, Expert Reviews in Molecular Medicine.

[53]  D. Landau,et al.  Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[54]  L. Trusolino,et al.  Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils , 2011, EMBO molecular medicine.

[55]  H. Koenig,et al.  Prostate-Specific Antigen-Based Screening for Prostate Cancer , 2011 .

[56]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[57]  J. Peto,et al.  Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study , 2011, The Lancet. Oncology.

[58]  G. Ceresoli,et al.  Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. , 2011, Lung cancer.

[59]  Tsun-Jen Cheng,et al.  Global Magnitude of Reported and Unreported Mesothelioma , 2011, Environmental health perspectives.

[60]  Edmund Neville,et al.  Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010 , 2010, Thorax.

[61]  F. Gleeson,et al.  Pleural procedures and thoracic ultrasound: British Thoracic Society pleural disease guideline 2010 , 2010, Thorax.

[62]  N. Maskell,et al.  Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010 , 2010, Thorax.

[63]  P. V. Van Schil,et al.  Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial , 2010, European Respiratory Journal.

[64]  I. Pastan,et al.  Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. , 2010, Lung cancer.

[65]  K. Nackaerts,et al.  Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. , 2010, American journal of respiratory and critical care medicine.

[66]  M. Metintaş,et al.  Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[67]  H. Dienemann,et al.  Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma , 2009, European Respiratory Journal.

[68]  Y. Chapman,et al.  A very public death: dying of mesothelioma and asbestos-related lung cancer (M/ARLC) in the Latrobe Valley, Victoria, Australia. , 2009, Rural and remote health.

[69]  C. Obasaju,et al.  Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  N. Müller,et al.  Malignant pleural mesothelioma: computed tomography and correlation with histology. , 2009, European journal of radiology.

[71]  F. Gleeson,et al.  Thoracic ultrasound in the diagnosis of malignant pleural effusion , 2008, Thorax.

[72]  I. Zuna,et al.  Computed Tomography, Positron Emission Tomography, Positron Emission Tomography/Computed Tomography, and Magnetic Resonance Imaging for Staging of Limited Pleural Mesothelioma: Initial Results , 2008, Investigative radiology.

[73]  S. Skates,et al.  Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[74]  J. Pollak,et al.  Management of Malignant Pleural Effusions , 2008, Seminars in respiratory and critical care medicine.

[75]  K. Nackaerts,et al.  Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[76]  V. Torri,et al.  Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials , 2008, British Journal of Cancer.

[77]  A. Nicholson,et al.  Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial , 2008, The Lancet.

[78]  R. Ramlau,et al.  Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  V. Seshan,et al.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. , 2008, The Journal of thoracic and cardiovascular surgery.

[80]  K. O'Byrne,et al.  Advances in the systemic therapy of malignant pleural mesothelioma , 2008, Nature Clinical Practice Oncology.

[81]  M. Mencoboni,et al.  Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[82]  A. Arber,et al.  The lived experience of patients with pleural mesothelioma. , 2008, International journal of palliative nursing.

[83]  BTS statement on malignant mesothelioma in the UK, 2007 , 2007, Thorax.

[84]  N. O'Rourke,et al.  A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[85]  A. Klein-Szanto,et al.  Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  H. Clayson The experience of mesothelioma in northern England. , 2007 .

[87]  H. Pass,et al.  A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes , 2007, Nature Reviews Cancer.

[88]  P. Jänne,et al.  Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  V. Rousson,et al.  Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. , 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[90]  A. Ceribelli,et al.  Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  C. Ryan,et al.  A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[92]  R. Vernhout,et al.  Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[93]  J. Seymour,et al.  Mesothelioma from the patient's perspective. , 2005, Hematology/oncology clinics of North America.

[94]  J. Creaney,et al.  Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. , 2005, Hematology/oncology clinics of North America.

[95]  B. Robinson,et al.  Advances in malignant mesothelioma. , 2005, The New England journal of medicine.

[96]  G. Giaccone,et al.  Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  O. Dalesio,et al.  Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. , 2005, Lung cancer.

[98]  S. Bretti,et al.  Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study , 2005, American journal of clinical oncology.

[99]  D. Maziak,et al.  Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. , 2005, Lung cancer.

[100]  S. Charman,et al.  Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[101]  R. Govindan,et al.  Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B , 2005, Clinical Cancer Research.

[102]  E. Chapman,et al.  Challenging the representations of cancer pain: Experiences of a multidisciplinary pain management group in a palliative care unit , 2005, Palliative and Supportive Care.

[103]  E. Scalzetti,et al.  Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. , 2005, Chest.

[104]  T. Treasure,et al.  Pleural mesothelioma: little evidence, still time to do trials , 2004, The Lancet.

[105]  M. Ladanyi,et al.  Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids , 2004, The Lancet.

[106]  W. Richards,et al.  Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. , 2004, The Journal of thoracic and cardiovascular surgery.

[107]  A. Musk,et al.  A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma , 2004, British Journal of Cancer.

[108]  D. Waller,et al.  Is there a role for pre-operative contrast-enhanced magnetic resonance imaging for radical surgery in malignant pleural mesothelioma? , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[109]  H. Clayson Suffering in mesothelioma: concepts and contexts , 2003 .

[110]  U. Gatzemeier,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  S. Larson,et al.  Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. , 2003, The Journal of thoracic and cardiovascular surgery.

[112]  M. Ladanyi,et al.  Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[113]  M. Paesmans,et al.  Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. , 2002, Lung cancer.

[114]  D. Fielding,et al.  A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma , 2002, British Journal of Cancer.

[115]  Michael J Schell,et al.  Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  A. Inui Cancer Anorexia‐Cachexia Syndrome: Current Issues in Research and Management , 2002, CA: a cancer journal for clinicians.

[117]  K. Rosenzweig,et al.  A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. , 2001, The Journal of thoracic and cardiovascular surgery.

[118]  H. Bayram,et al.  Malignant Pleural Mesothelioma Caused by Environmental Exposure to Asbestos in the Southeast of Turkey: CT Findings in 117 Patients , 2000, Respiration.

[119]  R. Loddenkemper,et al.  MRI and CT in the differential diagnosis of pleural disease. , 2000, Chest.

[120]  V. Indumathi,et al.  A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions , 2000, Respirology.

[121]  G. van Kaick,et al.  The german thorotrast study: recent results and assessment of risks. , 1999, Radiation research.

[122]  R. K. Bright,et al.  VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours , 1999, British Journal of Cancer.

[123]  C B Begg,et al.  Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. , 1999, AJR. American journal of roentgenology.

[124]  A. Alavi,et al.  Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. , 1998, Chest.

[125]  J. Herndon,et al.  Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. , 1998, Chest.

[126]  S. Steinberg,et al.  Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma , 1997, Annals of Surgical Oncology.

[127]  D. Howel,et al.  Routes of asbestos exposure and the development of mesothelioma in an English region. , 1997, Occupational and environmental medicine.

[128]  D. Yates,et al.  Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. , 1997, Thorax.

[129]  S J Mentzer,et al.  Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. , 1996, Annals of surgery.

[130]  V. Rusch A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. , 1995, Chest.

[131]  F. Rey,et al.  Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. , 1995, Chest.

[132]  V. Rusch,et al.  Pleurodesis using talc slurry. , 1994, Chest.

[133]  V. Rusch,et al.  A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  H. Pass,et al.  Simian virus 40-like DNA sequences in human pleural mesothelioma. , 1994, Oncogene.

[135]  D. Fuller Bleomycin versus Doxycycline: A Patient-Oriented Approach to Pleurodesis , 1993, The Annals of pharmacotherapy.

[136]  C. Cicala,et al.  SV40 induces mesotheliomas in hamsters. , 1993, The American journal of pathology.

[137]  I. Pastan,et al.  Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma , 1992, The American journal of surgical pathology.

[138]  C. Standertskjöld-Nordenstam,et al.  Computed Tomography of Pleural Lesions with Special Reference to the Mediastinal Pleura , 1986, Acta radiologica: diagnosis.

[139]  E. Butchart,et al.  Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. , 1976, Thorax.

[140]  John O. Prior,et al.  Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis. , 2014, Academic radiology.

[141]  W. Kinnear,et al.  British Thoracic Society Standards of Care Committee , 2014 .

[142]  M. Meyerson,et al.  Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP 1 , NF 2 , CDKN 2 A , and CUL 1 in Malignant Pleural Mesothelioma , 2014 .

[143]  L. Tanoue Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma , 2011 .

[144]  T. Powles,et al.  The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. , 2009, Lung cancer.

[145]  F. Galateau-Sallé,et al.  of Thoracic Surgeons for management of Malignant Pleural Mesothelioma , 2009 .

[146]  D. Waller,et al.  The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[147]  N. Hanna Assessing Quality of Life During Chemotherapy for Pleural Mesothelioma: Feasibility, Validity, and Results of Using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module , 2006 .

[148]  G. Hillerdal,et al.  Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases. , 2002, European journal of radiology.

[149]  A. Renshaw,et al.  The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. , 1997, Chest.

[150]  S. Sahn,et al.  Chemical Pleurodesis for Malignant Pleural Effusions , 1994, Annals of Internal Medicine.

[151]  J Espinosa Arranz,et al.  [Malignant mesothelioma]. , 1994, Medicina clinica.

[152]  I. Pastan,et al.  Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. , 1992, Cancer research.

[153]  G. Hillerdal Malignant mesothelioma 1982: review of 4710 published cases. , 1983, British journal of diseases of the chest.

[154]  J. Holland,et al.  Exposure to asbestos: psychological responses of mesothelioma patients. , 1983, American journal of industrial medicine.